9-oxo-9H-xanthene-3-carbonyl chloride | 115818-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 9-oxo-9H-xanthene-3-carbonyl chloride
• 英文别名: 9-oxoxanthene-3-carbonyl chloride
• CAS: 115818-25-2
• 化学式: C₁₄H₇ClO₃
• 分子量: 258.661
• InChiKey: HIVXMXWKDPTQKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  423.6±34.0 °C(Predicted)
• 密度：
  1.436±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  9-oxo-9H-xanthene-3-carbonyl chloride 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 15.0h， 生成 1-methyl-4-(9H-xanthen-3-ylmethyl)piperazine
  参考文献：
  名称：

  Identification of Compounds with Anti-West Nile Virus Activity

  摘要：

  The lack of antiviral compounds targeting flaviviruses represents a significant problem in the development of strategies for treating West Nile Virus (WNV), Dengue, and Yellow Fever infections. Using WNV high-throughput screening techniques developed in Our laboratories, we report the identification of several small molecule anti-WNV compounds belonging to four different structural classes including pyrazolines, xanthanes, acridines, and quinolines. The initial set of "hits" was further refined using cell viability-cytotoxicity assays to two 1,3,5-triaryl pyrazoline compounds: 1-(4-chlorophenylacetyl)-5-(4-nitrophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole and 1-benzoyl-5-(4-chlorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazole. On the basis of their activity and favorable therapeutic indexes, these compounds were identified as viable leads and subjected to additional evaluation using an authentic viral titer reduction assay employing an epidemic strain of WNV. The compounds were further evaluated in a transient replicon reporting system to gain insight into the mechanism of action by identifying the step at which inhibition takes place during viral replication. The results indicate the pyrazolines inhibit RNA synthesis, pointing to viral RNA polymerase, RNA helicase, or other viral replication enzymes as potential targets. Progress was also made in understanding the structural requirements for activity by synthesizing a focused chemical library of substituted pyrazolines. Preliminary SAR data are presented that show the aryl-rings are required for activity against WNV. More importantly, the results indicate WNV activity is tolerant to aryl-substitutions paving the way for the design and development of much larger combinatorial libraries with varied physicochemical properties.

  DOI：

  10.1021/jm051229y
• 作为产物：
  描述：

  2-苯氧基对苯二甲酸 在 氯化亚砜 、 硫酸 作用下， 反应 4.0h， 生成 9-oxo-9H-xanthene-3-carbonyl chloride
  参考文献：
  名称：

  具有拓扑异构酶活性的基于cr啶和d啶酮的抗疱疹药物的合成和评估。

  摘要：

  对于新的非核苷类抗病毒化合物的发现在治疗疱疹病毒感染方面具有重要意义，并且受到越来越多的关注，因为出现了核苷抗性菌株。使用全细胞病毒诱导的细胞致病性分析，我们测试了一系列取代的三芳基杂环化合物，包括a啶酮，x吨酮和a啶。进一步显示出对单纯疱疹-1和/或单纯疱疹2具有活性的化合物对拓扑异构酶活性的抑制作用，以深入了解其作用机理。结果表明，带有取代的羧酰胺和庞大的9-氨基官能团的the啶类似物能够抑制疱疹感染以及抑制超螺旋DNA的拓扑异构酶II松弛。鉴于氨苄青霉素的作用机理（密切相关，研究充分的9-氨基取代a啶），进一步在DNA拓扑异构酶II裂解试验中测试化合物，以确定化合物是否具有毒性。结果表明，在这项研究中合成的a啶通过与氨s碱不同的机制起作用，很可能是通过阻断拓扑异构酶与DNA的结合（类似于阿克拉比星）。这不仅表明治疗疱疹病毒感染的独特作用机制，而且对靶向拓扑异构酶II活性的抗癌药的开发

  DOI：

  10.1016/j.bmc.2006.04.044

文献信息

• [EN] TRICYCLIC DELTA OPIOID MODULATORS<br/>[FR] MODULATEURS DU RECEPTEUR OPIOIDE DOLLAR G(D) TRICYCLIQUES
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005003131A1

  公开（公告）日：2005-01-13

  The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

  这项发明涉及δ阿片受体调节剂。更具体地，该发明涉及三环δ-阿片调节剂。还描述了利用该发明的化合物治疗轻度至严重疼痛和各种疾病的药用和兽医组合物以及方法。
• Tricyclic delta-opioid modulators
  申请人：Dax Scott

  公开号：US20060030585A1

  公开（公告）日：2006-02-09

  The invention is directed to delta opioid receptor modulators. More specifically, the invention relates to tricyclic δ-opioid modulators. Pharmaceutical and veterinary compositions and methods of treating mild to severe pain and various diseases using compounds of the invention are also described.

  这项发明涉及δ阿片受体调节剂。更具体地，该发明涉及三环δ-阿片调节剂。还描述了利用该发明的化合物治疗轻度至严重疼痛和各种疾病的药用和兽医组合物以及方法。
• TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS
  申请人：Dax Scott

  公开号：US20090291979A1

  公开（公告）日：2009-11-26

  Disclosed are compounds, compositions and methods for treating various diseases and conditions, including pain. Such compounds are represented by Formula I as follows: wherein A, G, Y, R3, R4, and R5 are defined herein.

  本发明涉及用于治疗各种疾病和病症，包括疼痛的化合物、组合物和方法。这些化合物由以下式子I表示：其中A、G、Y、R3、R4和R5在此被定义。
• Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators
  申请人：Janssen Pharmaceutica NV

  公开号：US07553850B2

  公开（公告）日：2009-06-30

  Disclosed are compounds, compositions and methods for treating various diseases and conditions, including pain. Such compounds are represented by Formula I as follows: wherein A, G, Y, R3, R4, and R5 are defined herein.

  本发明涉及化合物、组合物和治疗各种疾病和病症的方法，包括疼痛。这些化合物由下式I所表示：其中A、G、Y、R3、R4和R5在此被定义。
• WO2007/30089
  申请人：——

  公开号：——

  公开（公告）日：——